Leonard Calabrese, DO

Hope on the Horizon: The Future of GCA Treatment

This video covers the following questions:

Let’s close this series by discussing the future of GCA management. How can clinicians continue to close the gaps in diagnosis and management, and what do you hope is on the horizon for GCA treatment? 

Thank you again to our panel, and thanks to our audience for watching. We hope you found this 

Peer Exchange to be useful and informative.

Videos

Reflecting on Trial Limitations in GCA: Painting a Future for IL-17A Targeting Therapies

Do these phase 3 results reflect the limitations of IL‑17A as a therapeutic target in GCA, or might issues in trial design, patient selection, or taper regimen explain the discrepancy between Phase II and Phase III outcomes? What role do you see for secukinumab in future GCA treatment?

Reflecting on Trial Limitations in GCA: Painting a Future for IL-17A Targeting Therapies 

Experts Discuss the REPLENISH Trial for Polymyalgia Rheumatica

Secukinumab is also being investigated as treatment for PMR in the REPLENISH-EXT trial. Please share your perspectives on this trial and the impact it may have on the treatment landscape.

Experts Discuss the REPLENISH Trial for Polymyalgia Rheumatica 

The Trial Design and Interim Results From the GCAptAIN Trial

Secukinumab, an IL‑17A inhibitor, emerged as a promising candidate for GCA based on Phase II data from last year showing 70% sustained remission at week 28 versus 20% with placebo (

Please share the results of Phase III GCAptAIN trial. How do you interpret these findings? (

Leonard Calabrese, DO

Articles